News
Ibogaine · Psychedelics · PTSD · Regulation
President Trump signed an executive order to fast-track research into the psychedelic drug ibogaine, currently a Schedule I controlled substance, aiming to treat PTSD in veterans and traumatic brain injuries, with government-sanctioned treatments potentially beginning as soon as this summer.
The order removes legal restrictions hindering extensive studies, establishes FDA protocols for safe therapeutic use, and improves data sharing on treatment. Preliminary research shows ibogaine alleviates mental illnesses, including addiction and PTSD, a critical need because over 14 million American adults suffer from serious mental illness and more than 6,000 US veterans commit suicide annually, according to the White House.
Dr. Mehmet Oz, Centers for Medicare & Medicaid Services Administrator, stated this is a "paradigm shift" from traditional "one-day-a-pill" models.
High-profile supporters include podcaster Joe Rogan, former Texas Gov. Rick Perry, and former Sen.
Kyrsten Sinema. The FDA previously granted Breakthrough Therapy designation to other psychedelics and expects to issue vouchers for three in-house research applications next week.
